+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID04561518

Global Long-Term Observational Study of Transthyretin-Mediated Amyloidosis Patients and Pre-symptomatic Carriers

Led by Alnylam Pharmaceuticals · Updated on 2026-10-13

1500

Participants Needed

40

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This observational study focuses on patients diagnosed with transthyretin TTR-mediated amyloidosis, including both hereditary and wild-type forms, as well as pre-symptomatic carriers of known disease-causing TTR variants. It aims to describe the epidemiological and clinical characteristics, natural history, and real-world clinical management of these patients. The study also evaluates the safety and effectiveness of the treatments patisiran and vutrisiran as they are used in routine clinical practice. Participants include those diagnosed with ATTR amyloidosis and pre-symptomatic carriers who follow their usual clinical care throughout the study. There are no investigational treatments administered as part of this study instead, participants continue with their standard care while data on disease progression and treatment outcomes are collected over time. Participants will be observed for up to 11 years, during which various health assessments will be conducted. These include evaluations of neuropathy disability, cardiomyopathy, exercise performance, and quality of life using different clinical scores and questionnaires. Adverse events and specific disease-related events will be monitored from enrollment. The long-term observation allows researchers to better understand disease progression and treatment impact in real-world settings.

CONDITIONS

Brief Title

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Research Team

A

Alnylam Clinical Trial Information Line

A

Alnylam Clinical Trial Information Line

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here